Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $49.5900 (-3.18%) ($49.5900 - $49.5900) on Fri. Jan. 15, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.17% (three month average) | RSI | 38 | Latest Price | $49.5900(-3.18%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -1.5% a day on average for past five trading days. | Weekly Trend | TGTX declines -0.6% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(66%) ARKG(62%) ARKK(58%) IBB(58%) IWO(58%) | Factors Impacting TGTX price | TGTX will decline at least -3.085% in a week (0% probabilities). VIXM(-41%) VXX(-36%) UUP(-19%) UNG(-3%) TLT(-1%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -3.085% (StdDev 6.17%) | Hourly BBV | -1.3 () | Intraday Trend | 0% | | | |
|
Resistance Level | $52.47 | 5 Day Moving Average | $51.73(-4.14%) | 10 Day Moving Average | $51.97(-4.58%) | 20 Day Moving Average | $52.47(-5.49%) | To recent high | -9.4% | To recent low | 96.6% | Market Cap | $6.281b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |